
RLMD
Healthcare · Biotechnology · $449.2M market cap
$4.21+0.05 (+1.2%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +22.8% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.14 | -0.12 | +14.3% |
| Aug 6, 2026 | After the close | -0.21 | -0.11 | +47.6% |
| May 13, 2026 | Time not confirmed | -0.20 | -0.22 | -12.8% |
| Mar 19, 2026 | After the close | -0.14 | -0.29 | -107.1% |
| Nov 13, 2025 | After the close | -0.04 | -0.30 | -650.0% |
| Aug 7, 2025 | Time not confirmed | -0.25 | -0.30 | -20.0% |
| May 12, 2025 | After the close | -0.31 | -0.58 | -87.1% |
| Mar 17, 2025 | After the close | -0.70 | -0.62 | +11.4% |
| Nov 7, 2024 | After the close | -0.64 | -0.72 | -12.5% |
| Aug 7, 2024 | After the close | -0.83 | -0.59 | +28.9% |
| May 8, 2024 | After the close | -0.86 | -0.72 | +16.3% |
| Mar 19, 2024 | After the close | -0.83 | -0.84 | -1.2% |
| Nov 8, 2023 | After the close | -0.91 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready…
| -0.73 |
| +19.8% |
| Aug 8, 2023 | After the close | -0.90 | -0.84 | +6.7% |
| May 11, 2023 | After the close | -0.89 | -0.87 | +2.2% |
| Mar 23, 2023 | After the close | -1.33 | -1.41 | -6.0% |
| Nov 10, 2022 | After the close | -1.47 | -1.26 | +14.3% |
| Aug 11, 2022 | After the close | -1.32 | -1.08 | +18.2% |
| May 5, 2022 | After the close | -1.22 | -1.40 | -14.8% |
| Mar 23, 2022 | After the close | -1.83 | -1.80 | +1.6% |
| Nov 11, 2021 | After the close | -1.55 | -2.42 | -56.1% |
| Aug 10, 2021 | After the close | -1.47 | -1.53 | -4.1% |
| May 12, 2021 | After the close | -1.42 | -1.33 | +6.3% |
| Mar 23, 2021 | After the close | -1.16 | -1.31 | -12.9% |
| Nov 12, 2020 | After the close | -0.94 | -1.05 | -11.7% |
| Aug 12, 2020 | After the close | -0.62 | -0.81 | -30.6% |
| May 15, 2020 | After the close | -0.37 | -0.66 | -78.4% |
| Mar 26, 2020 | After the close | -0.36 | -0.39 | -8.3% |
| Nov 13, 2019 | After the close | 0.00 | -0.38 | — |
| Sep 24, 2019 | After the close | — | -0.50 | — |
| May 15, 2019 | Before the open | — | -0.08 | — |
| Feb 13, 2019 | After the close | — | -0.28 | — |
| Nov 13, 2018 | After the close | — | -0.27 | — |
| Sep 28, 2018 | After the close | — | -0.27 | — |
| May 14, 2018 | After the close | — | -0.26 | — |
| Feb 12, 2018 | After the close | — | -0.46 | — |